Using a serum specimen, the test uses immunoassay methods to evaluate the levels of three liver–disease biomarkers: hyaluronic acid (HA), procollagen III amino–terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP–1). Because this is a multianalyte assay with algorithmic analysis (MAAA) test, the service includes an algorithmic analysis using patient data and the lab test results to report a risk score for liver fibrosis and liver–related clinical events that could occur within five years.
For clinical responsibility, terminology, tips and additional info
start codify free trial.